# Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma

> **NCT00441168** · PHASE2 · TERMINATED · sponsor: **Janssen-Cilag International NV** · enrollment: 30 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** adriamycin
- **DRUG:** bortezomib
- **DRUG:** dexamethasone
- **DRUG:** vincristine

## Key facts

- **NCT ID:** NCT00441168
- **Lead sponsor:** Janssen-Cilag International NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** TRIAL STOPPED due to a change in standard of care and the required patient numbers could no longer be achieved
- **Last updated:** 2014-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00441168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00441168, "Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00441168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*